OncoPrism has been clinically validated in Lung Cancer (NSCLC), the largest patient population being prescribed ICI Immunotherapy. Nothing seems more fitting during November, Lung Cancer Awareness Month. Congratulations to the Cofactor team whose talents and efforts are always aimed at making the most significant impact in patients' lives. Today was a win for Cofactor. More importantly, it is a win for cancer patients. https://lnkd.in/gMfX3DQ5
About us
Cofactor Genomics’s mission is to create diagnostics that have the ability to predict the patients that can benefit from immunotherapies. Using more insightful multidimensional biomarkers created with RNA and machine learning, Cofactor’s diagnostics offer greater predictive power than any current test. Instead of searching for isolated, single-analyte biomarkers or DNA mutations, Cofactor’s products create multidimensional biomarkers that better capture the complex immune response at the site of a tumor. Cofactor Genomics empowers clinicians to be better informed while making treatment decisions to improve patient outcomes.
- Website
-
https://cofactorgenomics.com
External link for Cofactor Genomics
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
- Founded
- 2015
- Specialties
- RNA, RNA-seq, NGS, Bioinformatics, and Diagnostics
Locations
-
Primary
Get directions
300 Brannan St
San Francisco, California, US
-
Get directions
4044 Clayton Ave
Saint Louis, MO 63110, US
-
Get directions
245 Main St
2nd Floor
Cambridge, Massachusetts 02142, US
Employees at Cofactor Genomics
Updates
-
The last 5 years of work building RNA models of disease and treatment response (HEMs), clinical trials understanding patient benefit from their use, health economic impact studies, and (recent) Medicare coverage have come together into a publication in the Journal of Immunotherapy of Cancer (JITC). This opus is only possible because of the amazing team at Cofactor Genomics, the hundreds of individuals involved in our PREDAPT partnered healthcare systems, and the thousands of biological and patient samples underlying development and validation. Congratulations to all those working tirelessly to improve outcomes for cancer patients across the nation. Onward and upward!
Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to Immunotherapy
businesswire.com
-
Team Cofactor is excited to have Dr. Howard McLeod joining us on the heels of Medicare coverage of Cofactor's OncoPrism test, a test with high accuracy predicting patients' response to immunotherapy. The next chapter involves integration into our partnered healthcare systems. Here we go! https://lnkd.in/gz5cHswM
Precision Medicine Global Thought Leader, Dr. Howard McLeod, Joins Cofactor Genomics’ Advisory Board as Cofactor Brings OncoPrism test to Partnered Hospitals
businesswire.com
-
A milestone was achieved today in ushering in a new generation of RNA + AI/machine learning powered predictive diagnostics. This marks a significant leap forward in bridging the precision medicine gap in immunotherapy. Congratulations to team Cofactor and the 38 US healthcare systems involved! https://lnkd.in/gHaaPgPY
Cofactor Genomics receives Medicare coverage for OncoPrism®, a machine learning-based RNA oncology test predicting immunotherapy response
businesswire.com
-
Proud to be invited to speak alongside many of my colleagues at this year’s RNA Leaders USA Congress. I'm speaking on the first day! I will be covering progress on Cofactor’s mission to build RNA models that solve the current precision medicine gap holding back the promise of cancer immunotherapy. Most importantly, I am excited to share recent clinical trial results in collaboration with dozens of US healthcare systems that show these RNA models are moving well beyond current clinical capabilities in predicting patient response to immunotherapy. https://lnkd.in/ggaDxbq3 #rnaleaders #RNA #mRNA #RNAi
-